Spinning off, cashing up and branching out: Commercialisation considerations for bioentrepreneurs in Australasia

Abstract

There are myriad issues to consider when commercialising a biotechnological innovation. In Australia, because of market structure, the tendency for biotechnology companies to list early in their life cycles has caused problems. A fledgling venture capital market in Australia has been partly to blame. The authors outline practical, strategic considerations for bioentrepreneurs in Australasia, focusing on innovations stemming from biomedical research.